Lol ! Yes of course, here is the source for the pdf :
https://www.beursduivel.be/Forum/Upload/2017/9806841.pdf
Yes it is related in the patent : "
In a specific embodiment, the needling device is adapted to perform needling of a human scalp for promoting hair growth, of skin tissue for skin repair, or of scar tissue for scar removal "
-------------------------------------------------------------------------------------------------------------------------------------------------
I try to find some informations . There are 3 patents (2017).
There are 2 drugs tested in the last one
DP-2 antagonists used: AM211 (Amira), Setipirant (Actelion; data not shown).
-------------------------------------------------------------------------------------------------------------------------------------------------
1. Patent "
Methods for generating new hair follicles, treating baldness, and hair removal " Inventors: George Cotsarelis, Mayumi Ito . Publication date :
Jul 11, 2017
The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair pigmentation
(...) FIG. 23.
Pigmented hair follicle neogenesis observed in the skin of Dkk1-expressing mice following EDIHN A. 3.2× magnification. B. 8× magnification.
(...)
epidermal disruption by a method of the present invention converts the skin back, in another embodiment, to an embryonic-like state, in which the follicle regenerates. In another embodiment, a subsequent window of opportunity is created, during which the number and size of new HF in the skin can be manipulated. In another embodiment, the administration of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell during this window causes regeneration of larger and more numerous HF. The morphology of HF in abraded skin is similar to that of embryonic HF (Example 1-2 and subsequent Examples), and the markers expressed are similar as well.
(...)
EDIHN,” in another embodiment, refers to HF neogenesis induced by disruption of the epithelial layer. In another embodiment, the term refers to HF neogenesis induced by abrasion. In another embodiment, the term refers to HF neogenesis induced by wounding. In another embodiment, the term refers to HF neogenesis induced by disruption of the epithelial layer, followed by administration of a compound or factor that promotes a differentiation of an uncommitted epidermal cell into a HF cell
-------------------------------------------------------------------------------------------------------------------------------------------------
2. Patent "
Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph " Inventors :
Cotsarelis and Luis Garza. Publication date :
Dec 1, 2016
[0467]
In another embodiment, the present invention provides a pharmaceutical composition, comprising an inhibitor of prostaglandin D2 activity and a pro-hair growth prostaglandin. In another embodiment, the pro-hair growth prostaglandin is a prostaglandin E1. In another embodiment, the pro-hair growth prostaglandin is a prostaglandin E2. In another embodiment, the pro-hair growth prostaglandin is a prostaglandin F2a. In another embodiment, the pro-hair growth prostaglandin is any other pro-hair growth prostaglandin known in the art. Each possibility represents a separate embodiment of the present invention.
-------------------------------------------------------------------------------------------------------------------------------------------------
3. Patent "
Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 " Inventors:
Cotsarelis. Publication date:
2 Feb 2017
DP-2 antagonists reversed PGD2-mediated human hair growth inhibition in a dose-dependent manner in vitro by reducing PGD2-triggered apoptosis and maintaining proliferation of keratinocytes. Hair follicles from approximately half of the alopecia patients exhibited little susceptibility to PGD2's effect in vitro. SNPs in the human DP-2 gene were identified that are associated with hair growth inhibition by PGD2. These findings underscore the role of DP-2 in regulating hair growth and indicate that DP-2 can be an effective approach in preventing and/or treating androgenetic alopecia in patients sensitive to PGD2. Furthermore, the SNPs identified here can be used to identify patients who will benefit from treatment.
DRUGS:
[0089] DP-2 antagonists used: AM211 (Amira), Setipirant (Actelion; data not shown).
View attachment 60370 View attachment 60371
View attachment 60369
